To Evaluate the Therapeutic Efficacy of Vildagliptin on Microalbuminuria in Type 2 Diabetes Mellitus

Introduction: Diabetic kidney disease (DKD) represents one of the most frequent microvascular complications of diabetes with an overall prevalence of approximately 40% in type 2 diabetes population. Microalbuminuria is one of the most serious problems in type 2 DM. Vildagliptin, DPP-4 inhibitors, is a novel oral anti-diabetic drug for the treatment of type 2 diabetes mellitus (T2DM). The objective of the study was to evaluate the therapeautic efficacy of vildagliptin on microalbuminuria in type 2 diabetes mellitus.